BRISBANE, Calif., May 30, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, will highlight CareDx's Olerup pre-transplant diagnostics at the 31st European Immunogenetics and Histocompatibility Conference from May 30 - June 2, 2017 in Mannheim/Heidelberg, Germany.
News for Olerup product portfolio at the meeting includes:
- Olerup SSP Foundational human leukocyte antigen (HLA) typing. Continued leader in the field with timely updates of new HLA alleles.
- Olerup QTYPE Speed and precision in HLA typing on both Roche and Applied Biosystems (ABI) instruments. Rapid typing is vital for deceased donor transplants.
- Olerup SBT Accurate sequence based typing including reagents for sequencing, Heterozygous Ambiguity Resolution Primers (HARPS), and software (Assign SBT). Sequencing based technology (SBT) sets the benchmark for high-resolution HLA typing.
CareDx also hosts a symposium on Wednesday, May 31,
12:00-1:00 titled "Ensuring transplant success through improvements in diagnostics" with Anna Hedlund, Head of Research and Development, providing key updates to Olerup products and John J. Sninsky, Chief Scientific Officer for CareDx, presenting "The Evolving Transplant Testing Continuum".
The CareDx booth will highlight key innovations with a video on Olerup QTYPE and a demonstration of SCORE 6, the recently developed software for the Olerup QTYPE 11 product.
"We look forward to communicating the exciting progress on new products for the HLA community at EFI this year," said Anders Karlsson, Chief International Business Officer. "Even though short term outcomes for transplant patients have improved significantly,
long term outcomes remain unchanged. We, at CareDx, would like to contribute to leveraging information and data analytics in the pre-transplant setting to improve post-transplant patient management."
CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value solutions for transplant recipients. CareDx offers products across the transplant testing continuum, including AlloMap® and AlloSure™ for post-transplant surveillance and
Olerup SSP®, Olerup QTYPE®, and Olerup SBT™ for pre-transplant HLA testing.
For more information, please visit: www.CareDx.com.
Forward Looking Statements
This press release contains forward-looking statements about our business, research, development and commercialization efforts including, but not limited to the development, commercialization, utility, performance and adoption of AlloSure. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including risk associated with successful research,
development and planned commercialization of our technologies, that are described in our filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2016 filed by us with the SEC on April 21, 2017. Any of these may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
Sasha King, Head of Marketing
T: +1 415-287-2393
Source: CareDx, Inc.
News Provided by Acquire Media